clinical trial · NCT06994143
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis (RACLN-978
brief summary
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
started
May 19, 2025
primary completion
Dec 30, 2027
completion
Dec 30, 2028
last updated
Jul 4, 2025
official title
A Phase I, Open-Label Study of CLN-978 in Patients With Treatment-Refractory Rheumatoid Arthritis (RA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol